Sex, hormones, and Alzheimer's disease

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 60, Issue 6, 2005, Pages 736-743

  Baum, Larry W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; PROGESTERONE DERIVATIVE; TESTOSTERONE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DOWN REGULATION; DRUG USE; HORMONE SUBSTITUTION; HUMAN; LIFESPAN; MEDICAL LITERATURE; META ANALYSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE;

EID: 21144444236     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/60.6.736     Document Type: Review

References (127)

1. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365-375.
2. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology. 1993;43:515-519.
3. Vas CJ, Pinto C, Panikker D, et al. Prevalence of dementia in an urban Indian population. Int Psychogeriatr. 2001;13:439-450.
4. Wang W, Wu S, Cheng X, et al. Prevalence of Alzheimer's disease and other dementing disorders in an urban community of Beijing, China. Neuroepidemiology. 2000;19:194-200.
5. García García FJ, Sánchez Ayala MI, Pérez Martin A, et al. Prevalencia de demencia y de sus subtipos principales en sujetos mayores de 65 años: efecto de la educación y ocupación. Estudio Toledo. Med Clin (Bare). 2001;116:401-407.
6. Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol. 2001;153:132-136.
7. Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology. 2001;57:985-989.
8. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ. 1994;150:899-912.
9. Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology. 2000;55:198-204.
10. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. EURODEM Incidence Research Group. Neurology. 1999;53: 1992-1997.
11. Lerner AJ. Alzheimer's disease in males: endocrine issues and prospects. J Clin Endocrin Metab. 1999;84:3416-3419.
12. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383-390.
13. Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N. Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:1-12.
14. Rockwood K, Macknight C, Wentzel C, et al. The diagnosis of "mixed" dementia in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC). Ann N Y Acad Sci. 2000;903:522-528.
15. Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology. 1997;48:132-138.
16. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54:2072-2077.
17. Barnes LL, Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Gender, cognitive decline, and risk of AD in older persons. Neurology. 2003;60:1777-1781.
18. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156:445-453.
19. Baum L, Baum E. Progressive diseases: interpretation of genetic data. J Theoretical Med. 1999;2:1-7.
20. Lapane KL, Gambassi G, Landi F, Sgadari A, Mor V, Bernabei R. Gender differences in predictors of mortality in nursing home residents with AD. Neurology. 2001;56:650-654.
21. Agüero-Torres H, Fratiglioni L, Winblad B. Natural history of Alzheimers disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project. Int J Geriatr Psychiatry. 1998;13:755-766.
22. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc. 1998;46:444-452.
23. Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002; 59:1764-1767.
24. Cobb JL, Wolf PA, Au R, White R, D'Agostino RB. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology. 1995;45:1707-1712.
25. Hill LR, Klauber MR, Salmon DP, et al. Functional status, education, and the diagnosis of dementia in the Shanghai survey. Neurology. 1993;43:138-145.
26. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology. 1993;43:13-20.
27. Letenneur L, Launer LJ, Andersen K, et al. Education and the risk for Alzheimer's disease: sex makes a difference. EURODEM pooled analyses. EURODEM Incidence Research Group. Am J Epidemiol. 2000;151:1064-1071.
28. Qiu C, Backman L, Winblad B, Aguero-Torres H, Fratiglioni L. The influence of education on clinically diagnosed dementia incidence and mortality data from the Kungsholmen Project. Arch Neurol. 2001; 58:2034-2039.
29. Stern Y, Tang MX, Denaro J, Mayeux R. Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann Neurol. 1995;37:590-595.
30. Hogervorst E, Williams J, Budge M, Riedel W, Jolies J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101:485-512.
31. Clark AF, Marcellus S, deLory B, Bird CE. Plasma testosterone free index: a better indicator of plasma androgen activity? Fertil Steril. 1975;26:1001-1005.
32. Barren-Connor E, Goodman-Gruen D. Cognitive function and endogenous sex hormones in older women. J Am Geriatr Soc. 1999; 47:1289-1293.
33. Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab. 1999;84:3681-3685.
34. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62: 188-193.
35. Henderson VW, Hogervorst E. Testosterone and Alzheimer disease: is it men's turn now? Neurology. 2004;62:170-171.
36. Pennanen C, Laakso MP, Kivipelto M, Ramberg J, Soininen H. Serum testosterone levels in males with Alzheimer's disease. J Neuroendocrinol. 2004;16:95-98.
37. Paoletti AM, Congia S, Lello S, et al. Low androgenization index in elderly women and elderly men with Alzheimer's disease. Neurology. 2004;62:301-303.
38. Flood JF, Fair SA, Kaiser FE, La Regina M, Morley JE. Age-related decrease of plasma testosterone in SAMP8 mice-replacement improves age-related impairment of learning and memory. Physiol Behav. 1995;57:669-673.
39. Morley JE. Testosterone and behavior. Clin Geriatr Med. 2003;19: 605-616.
40. Wisniewski AB, Nguyen TT, Dobs AS. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women. Horm Res. 2002;58:150-155.
41. Gandy S, Almeida O, Fonte J, et al. Chemical andropause and amyloid-β peptide. JAMA. 2001;285:2195-2196.
42. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517-1521.
43. Zee RF, Trivedi MA. The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev. 2002;12:65-109.
44. Savaskan E. Estrogen-related neuroprotection: implications for neurodegenerative disorders. XX vs. XY. 2003;1:32-38.
45. Paganini-Hill A, Henderson VM. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996;156:2213-2217.
46. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
47. Shumaker SA, Legault C, Thai L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
48. Whitmer RA, Haan MN, Miller JW, Yaffe K. Hormone replacement therapy and cognitive performance: the role of homocysteine. J Gerontol Med Sci. 2003;58A:324-330.
49. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289: 2673-2684.
50. Rice MM, Graves AB, McCurry SM, et al. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: the Kame Project. Arch Intern Med. 2000;160:1641-1649.
51. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24: 1757-1761.
52. Zhu XD, Bonet B, Knopp RH. Estradiol 17β inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees. Atherosclerosis. 2000;148:31-41.
53. Barrett-Connor E, Slone S, Greendale G, et al. The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas. 1997;27:261-274.
54. Gelfand MM, Fugere P, Bissonnette F, et al. Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding. Menopause. 1997;4: 10-18.
55. Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: influence of various progestogens and duration of therapy. Arch Intern Med. 1996;156:1693-1700.
56. Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology. 2002;143:205-212.
57. 1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Rev. 2001;37: 116-132.
58. Maurice T. Improving Alzheimer's disease-related cognitive deficits with sigma 1 receptor agonists. Drug News Perspect. 2002;15:617-625.
59. 25-35-amyloid peptide-treated mice. Behav Brain Res. 2002;134:239-247.
60. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99:459-496.
61. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403.
62. Perry EK, Perry RH. Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet. 1977;1:189.
63. Bertrand D, Valera S, Bertrand S, Ballivet M, Rungger D. Steroids inhibit nicotinic acetylcholine receptors. Neuroreport. 1991;2: 277-280.
64. Damaj MI. Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. J Pharmacol Exper Ther. 2001;296: 132-140.
65. Garbus I, Bouzat C, Barrantes FJ. Steroids differentially inhibit the nicotinic acetylcholine receptor. Neuroreport. 2001;12:227-231.
66. Valera S, Ballivet M, Bertrand D. Progesterone modulates a neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci USA. 1992;89: 9949-9953.
67. Ke L, Lukas RJ. Effects of steroid exposure on ligand binding and functional activities of diverse nicotinic acetylcholine receptor subtypes. J Neurochem. 1996;67:1100-1112.
68. Ott BR, Belazi D, Lapane KL. Cognitive decline among female: estrogen users in nursing homes. J Gerontol Med Sci. 2002;57A: M594-M598.
69. Alving B. NIH asks participants in Women's Health Initiative; estrogen-alone study to stop study pills, begin follow-up phase. March 2, 2004. Available at: http://www.nih.gov/news/pr/mar2004/nhlbi-02.htm
70. Asthana S. Estrogen and cognition: the story so far. J Gerontol Med Sci. 2003;58A:322-323.
71. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2002;3:CD003799.
72. Chae HS, Bach JH, Lee MW, et al. Estrogen attenuates cell death induced by carboxy-terminal fragment of amyloid precursor protein in PC12 through a receptor-dependent pathway. J Neurosci Res. 2001; 65:403-407.
73. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod. 2002; 67:1379-1385.
74. Gibbs RB. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement. Brain Res. 1998;787:259-268.
75. Gibbs RB. Effects of gonadal hormone replacement on measures of basal forebrain cholinergic function. Neuroscience. 2000;101:931-938.
76. Honjo H, Kikuchi N, Hosoda T, et al. Alzheimer's disease and estrogen. J Steroid Biochem Mol Biol. 2001;76:227-230.
77. Hosoda T, Nakajima H, Honjo H. Estrogen protects neuronal cells from amyloid β-induced apoptotic cell death. Neuroreport. 2001;12: 1965-1970.
78. Zhang L, Rubinow DR, Xaing G, et al. Estrogen protects against beta-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of Akt. Neuroreport. 2001;12:1919-1923.
79. Petanceska SS. Age-associated androgen deficiency and Alzheimer's disease: a case in the making? J Alzheimers Dis. 2003;5:271-273.
80. Almeida OP, Flicker L. Testosterone and dementia: too much ado about too little data. J Br Menopause Soc. 2003;9:107-110.
81. Hogervorst E, Combrinck M, Smith AD. Testosterone and gonadotropin levels in men with dementia. Neuroendocrinol Lett. 2003;24: 203-208.
82. Hoskin EK, Tang MX, Manly JJ, Mayeux R. Elevated sex-hormone binding globulin in elderly women with Alzheimer's disease. Neurobiol Aging. 2004;25:141-147.
83. Gillett MJ, Martins RN, Clamette RM, Chubb SA, Brace DG, Yeap BB. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis. 2003;5:267-269.
84. Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male. 2003;6:13-17.
85. Kenny AM, Fabregas G, Song CW, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol Med Sci. 2004;59A: 75-78.
86. Cherrier MM, Craft S, Matsumoto AH. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J Androl. 2003;24:568-576.
87. Bruce-Keller AJ, Keeling JL, Keller JN, Huang FF, Camondola S, Mattson MP. Antiinflammatory effects of estrogen on microglial activation. Endocrinology. 2000;141:3646-3656.
88. McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol. 2002;8:529-538.
89. Blaustein JD. Estrogen receptor immunoreactivity in rat brain: rapid effects of estradiol injection. Endocrinology. 1993;132:1218-1224.
90. Brown TJ, Scherz B, Hochberg RB, MacLusky NJ. Regulation of estrogen receptor concentrations in the rat brain: effects of sustained androgen and estrogen exposure. Neuroendocrinology. 1996;63:53-60.
91. DonCarlos L, Malik K, Morrell JI. Region-specific effects of ovarian hormones on estrogen receptor immunoreactivity. Neuroreport. 1995;6:2054-2058.
92. Osterlund M, Kuiper GG, Gustafsson JA, Kurd YL. Differential distribution and regulation of estrogen receptor-alpha and -beta mRNA within the female rat brain. Brain Res Molec Brain Res. 1998; 54:175-180.
93. Simerly RB, Young BJ. Regulation of estrogen receptor messenger ribonucleic acid in rat hypothalamus by sex steroid hormones. Mol Endocrinol. 1991;5:424-432.
94. Braak H, Braak E. Neuropathologic staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.
95. Braak E, Braak H, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol (Berl). 1994;87:554-567.
96. Hyman BT, Van Horsen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984:225:1168-1170.
97. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994;140:256-261.
98. Waring SC, Rocca WA, Peteresen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD. Neurology. 1999;52:965-970.
99. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885-890.
100. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990;250:279-282.
101. Morishima Y, Gotoh Y, Zieg J, et al. β-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci. 2001;21: 7551-7560.
102. Wei W, Wang X, Kusiak JW. Signaling events in amyloid β-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol. Chem. 2002;277:17649-17656.
103. Nuedling S, Kahlert S, Loebbert K, Meyer R, Vetter H, Grohe C. Differential effects of 17beta-estradiol on mitogen-activated protein kinase pathways in rat cardiomyocytes. FEBS Lett. 1999;454: 271-276.
104. Prifti S, Mall P, Strowitzki T, Rabe T. Synthetic estrogens-mediated activation of JNK intracellular signaling molecule. Gynecol Endocrinol 2001;15:135-141.
105. Jezierski MK, Sturm AK, Scarborough MM, Sohrabji F. NGF stimulation increases JNK2 phosphorylation and reduces caspase-3 activity in the olfactory bulb of estrogen-replaced animals. Endocrinology. 2001;142:2401-2404.
106. Sawada H, Ibi M, Kihara T, et al. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J. 2000;14: 1202-1214.
107. Barrett-Connor E, Kritz-Silverstein D. Gender differences in cognitive function with age: the Rancho Bernardo study. J Am Geriatr Soc. 1999;47:159-164.
108. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994;140: 262-267.
109. Finit H. Estrogens in the pathogenesis and treatment of Alzheimer's disease in postmenopausal women. Ann N Y Acad Sci. 1994;743: 233-238.
110. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295-301.
111. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000;283:1007-1015.
112. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000;54:2061-2066.
113. Balderischi M, DiCarlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 1998;50:996-1002.
114. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwaiter J. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol. 1994;51:896-900.
115. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease. Neurology. 1996;48:1517-1521.
116. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci 1995;7:334-337.
117. Amaducci LA, Fratiglioni L, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology. 1986;36:922-931.
118. Borenstein-Graves A, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol. 1990;28:766-774.
119. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology. 1990;40:1698-1707.
120. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol. 1984;15:335-341.
121. Lerner A, Koss E, Debanne S, Rowland D, Smith K, Friedland R. Smoking and oestrogen replacement therapy as protective factors against AD. Lancet. 1997;349:403-404.
122. Slooter AJC, Bronzova J, Witteman JCM, van Broekhoven C, van Duijn C. Estrogen use and early onset Alzheimer's disease: a population based study. J Neurol Neurosurg Psychiat. 1999;67:779-781.
123. Petitti DB, Buckwalter G, Crooks VC, Chiu V. Prevalence of dementia in users of hormone replacement therapy as defined by prescription data. J Gerontol Med Sci. 2002;57A:M532-M538.
124. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res. 2000;113:117-120.
125. Wang HX, Fratiglioni L, Frisoni GB, Viitanen M, Winblad B. Smoking and the occurrence of Alzheimer's disease: cross-sectional and longitudinal data in a population-based study. Am J Epidemiol. 1999;149:640-644.
126. Ott A, Slooter AJC, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet. 1998;351;1840-1843.
127. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.